Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer

Sugaya, Masakazu; Sugio, Kenji; Nagashima, Akira; Nakanishi, Ryoichi; Sakata, Hisanobu; Nakanishi, Koki; Ono, Kenji; Uramoto, Hideshi; Hanagiri, Takeshi; Yasumoto, Kosei

doi:10.1200/jco.2005.23.16_suppl.7258

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CP regimen is considered as a standard chemotherapy regimen for recurrent and advanced lung cancer ( 42 – 46 ). We used the regimen of bi-weekly paclitaxel plus carboplatin to be able to complete the adjuvant chemotherapy without interruption due to side effects.…”

Section: Discussionmentioning

confidence: 99%

The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross‑complementation group 1 and class III β‑tubulin, and the therapeutic effect of S‑1 or carboplatin plus paclitaxel in non‑small‑cell lung cancer

et al. 2018

View full text Add to dashboard Cite

Previous studies have reported that the expressions of specific proteins may predict the efficacy of chemotherapy agents for non-small cell lung cancer (NSCLC) patients. The present study evaluated the expression of proteins hypothesized to be associated with the effect of chemotherapeutic agents in 38 NSCLC patients with pathological stage II and IIIA. The subjects received carboplatin plus paclitaxel (CP) or S-1 as adjuvant chemotherapy following complete resection. The protein expressions evaluated were those of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phsphoribosyltransferase (OPRT), which were suspected to be associated with the effect of S-1 agents, excision repair cross-complementation group 1 (ERCC1), which was suspected to be associated with the effect of platinum-based agents, and class III β-tubulin (TUBB3), which was suspected to be associated with the effect of taxane-based agents. The positive rate of TS was 55.3% (n=21/38), DPD was 57.9% (n=22/38), OPRT was 42.1% (n=16/38), ERCC1 was 47.4% (n=18/38) and TUBB3 was 44.7% (n=17/38). Among the patients who received S-1 adjuvant chemotherapy, TS-negative cases demonstrated a significantly better disease-free survival than positive cases. Thus, TS protein expression may have been a factor that predicted the effect of S-1 agent as adjuvant chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross‑complementation group 1 and class III β‑tubulin, and the therapeutic effect of S‑1 or carboplatin plus paclitaxel in non‑small‑cell lung cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…P-stage was determined according to the TNM classification (Union for International Cancer Control TNM staging system, 7th edition). Patients with p-stage IB disease who were eligible for adjuvant chemotherapy were encouraged to participate in clinical trials ( 11 , 12 ), and 10 patients received adjuvant chemotherapy (carboplatin-based chemotherapy in 8 patients and tegafur plus uracil in 2 patients). Other patient characteristics are shown in Table I .…”

Section: Methodsmentioning

confidence: 99%

CD155 expression and its clinical significance in non‑small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

“…Because of concern over possible association between the dose of anticancer agents and the development of BPF, the drug administration regimen was changed slightly from monthly to biweekly carboplatin (AUC 3; 350 mg/body) plus paclitaxel (90 mg/m 2 = 162 mg/ body). 5 He received a further three courses of systemic chemotherapy using the biweekly regimen. Then, the patient visited our hospital every 2 months for strict follow-up, and he was doing well with no evidence of recurrence of lung cancer 5 years after the initial surgery.…”

Section: Case Reportmentioning

confidence: 99%

Successful treatment of lung adenocarcinoma in an 18-year-old man

Uramoto

Hanagiri

et al. 2011

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Primary lung cancer is an extremely rare neoplasm in young adults. We report a case of a primary lung adenocarcinoma in an 18-year-old man who presented for examination of a solitary nodule located in the right lower lobe of the lung. A right lower lobectomy was performed with an incomplete resection because of pleural dissemination (pT4N2M0 stage IIIB adenocarcinoma). Intrathoracic chemotherapy (cisplatin, 50 mg/body) was administered initially, followed by systemic chemotherapy (carboplatin + paclitaxel). A bronchopleural fistula occurred 2 months postoperatively and was successfully treated with conservative therapy, including thoracic drainage, intrathoracic fibrin glue administration, and transbronchial superglue administration. Thereafter, a total of five courses of systemic chemotherapy with minor changes in the administration regimen were performed. The patient was alive and with no evidence of recurrence at his 5-year follow-up.

show abstract

Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer

Cited by 6 publications

References 0 publications

CD155 expression and its clinical significance in non‑small cell lung cancer

Successful treatment of lung adenocarcinoma in an 18-year-old man

Contact Info

Product

Resources

About